The market expects Amneal Pharmaceuticals (AMRX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to b ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number 001-38485 Amneal Pharmaceuticals, Inc. 400 Crossing Boulevard, Bridgewater, NJ (Address of principal executive offic ...

Q4 2024 Earnings Call Q4 2024 earnings call Agenda 1 Strategy & Business Update Chirag and Chintu Patel, Co-founders and Co-CEOs 2 Financial Results Tasos Konidaris, EVP & CFO 3 Q&A Chirag Patel, Co-CEO and President Joe Renda, SVP - Specialty 3 Cautionary statement on forward looking statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking ...

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President and Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President and Chief Financial Officer Joe Renda - Senior Vice President and Chief Commercial Officer, Specialty Jason Daly - Chief Legal Officer Conference Call Participants Chris Schott - J.P. Morgan David Amsellem ...

Amneal Pharmaceuticals (AMRX) reported $730.52 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 18.4%. EPS of $0.12 for the same period compares to $0.14 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $708.21 million, representing a surprise of +3.15%. The company delivered an EPS surprise of -20.00%, with the consensus EPS estimate being $0.15.While investors scrutinize revenue and earnings changes year-over-year and how they com ...

Group 1: Earnings Performance - Amneal Pharmaceuticals reported quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.15 per share, and down from $0.14 per share a year ago, representing an earnings surprise of -20% [1] - The company posted revenues of $730.52 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 3.15%, compared to year-ago revenues of $616.98 million [2] - Over the last four quarters, Amneal has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Group 2: Stock Performance and Outlook - Amneal shares have increased by approximately 5.8% since the beginning of the year, while the S&P 500 has declined by -0.3% [3] - The sustainability of the stock's immediate price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the coming quarter is $0.16 on revenues of $704.43 million, and for the current fiscal year, it is $0.68 on revenues of $2.92 billion [7] Group 3: Industry Context - The Medical - Drugs industry, to which Amneal belongs, is currently in the top 34% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Amneal's stock performance [5][6]

Financial Performance - Q4 2024 net revenue was $731 million, an 18% increase from $617 million in Q4 2023[3] - Full year 2024 net revenue reached $2.79 billion, a 17% increase compared to $2.39 billion in 2023[3] - Q4 2024 adjusted net income was $40 million, with adjusted EBITDA of $155 million, reflecting a 9% increase from the previous year[3] - Full year 2024 adjusted EBITDA was $627 million, a 12% increase from the prior year[3] - Adjusted diluted EPS for full year 2024 was $0.58, a 9% decrease from $0.64 in 2023[3] - The company provided 2025 financial guidance of $3.0 to $3.1 billion in net revenue and $650 to $675 million in adjusted EBITDA[4] Segment Performance - Affordable Medicines segment revenue grew by 21% in Q4 2024, driven by new product launches and biosimilars[3] - AvKARE segment revenue increased by 14% in Q4 2024 due to new product launches[3] - Specialty segment revenue grew by 16% in Q4 2024, supported by key branded products including CREXONT®[3] - The Specialty Segment reported net revenue of $445,749 for the year ended December 31, 2024, up from $390,457 in 2023, marking a 14.2% increase[47] - The AvKARE Segment achieved net revenue of $662,945 for the year ended December 31, 2024, compared to $531,749 in 2023, representing a 24.7% growth[54] Expenses and Losses - Research and development expenses increased to $190.7 million for the year ended December 31, 2024, compared to $164.0 million in 2023, reflecting a 16.3% rise[17] - The net loss attributable to Amneal Pharmaceuticals, Inc. for the year ended December 31, 2024, was $116.9 million, compared to a net loss of $84.0 million in 2023, representing a 38.9% increase in losses[17] - The company incurred stock-based compensation expenses of $7,209 thousand for the three months ended December 31, 2024, compared to $5,974 thousand in the same period of 2023[30] - The company recorded a significant reduction in legal-related charges, with net charges of $96,692 in 2024 compared to $10,000 in 2023[40] Assets and Liabilities - Total current assets increased to $1,587.8 million as of December 31, 2024, from $1,377.9 million in 2023, marking a 15.2% growth[19] - Total liabilities decreased to $3,501.4 million as of December 31, 2024, from $3,472.6 million in 2023, indicating a slight reduction in overall liabilities[19] - Cash and cash equivalents at the end of the period increased to $110.6 million in 2024, up from $91.5 million in 2023, a growth of 20.5%[21] Cash Flow and Operating Activities - The company reported a net cash provided by operating activities of $295.1 million for the year ended December 31, 2024, compared to $345.6 million in 2023, a decrease of 14.6%[21] Corporate Structure and Strategy - The company implemented a reorganization plan on November 7, 2023, converting to a more traditional C-corporation structure[17] - The company plans to continue focusing on expanding its product pipeline and enhancing operational efficiencies in the upcoming fiscal year[17] - The company plans to continue focusing on market expansion and new product development to drive future growth[41] Leverage and Debt - The company reduced net leverage to 3.9x, ahead of its commitment to be below 4x[2] - The net leverage ratio improved to 3.9x as of December 31, 2024, down from 4.8x as of December 31, 2023[26] - Total gross debt as of December 31, 2024, was $2,584,835 thousand, a decrease from $2,766,826 thousand as of December 31, 2023[26]

Wall Street analysts forecast that Amneal Pharmaceuticals (AMRX) will report quarterly earnings of $0.15 per share in its upcoming release, pointing to a year-over-year increase of 7.1%. It is anticipated that revenues will amount to $707.4 million, exhibiting an increase of 14.7% compared to the year-ago quarter.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates duri ...

Amneal Pharmaceuticals (AMRX) shares rallied 6% in the last trading session to close at $8.30. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 9.8% loss over the past four weeks.The sudden soaring of the stock price can be attributed to positive investor expectations regarding the strong market potential of its generics as well as specialty pharmaceutical products portfolios. This pharmaceutical company is ex ...